Suboxone

RSS

Withdrawn

This medicine's authorisation has been withdrawn

buprenorphine / naloxone
MedicineHumanWithdrawn

Bulgarian is available via eTranslation, the European Commission's machine translation service.

Translate to Bulgarian | Important information about machine translation

  • Application under evaluation
  • CHMP opinion
  • European Commission decision

Overview

On 11 September 2026, the European Commission withdrew the marketing authorisation for Suboxone (buprenorphine / naloxone) in the European Union (EU). The withdrawal was at the request of the marketing authorisation holder, Indivior Europe Limited, which notified the European Commission of its decision to permanently discontinue the marketing of the product for commercial reasons.

Suboxone was granted marketing authorisation in the EU on 26 September 2006 for the substitution treatment of opioid drug dependence, within a framework of medical, social and psychological treatment. Suboxone was used in adults and adolescents over 15 years of age who had agreed to be treated for addiction.

The marketing authorisation was initially valid for a 5-year period. It was then granted unlimited validity in 2011.

Several therapeutic alternatives remain available, as either buprenorphine alone or buprenorphine in combination with naloxone, in different pharmaceutical forms.

български (BG) (154.63 KB - PDF)

Виж

español (ES) (126.92 KB - PDF)

Виж

čeština (CS) (150.58 KB - PDF)

Виж

dansk (DA) (127.12 KB - PDF)

Виж

Deutsch (DE) (130.69 KB - PDF)

Виж

eesti (ET) (123.34 KB - PDF)

Виж

ελληνικά (EL) (155.89 KB - PDF)

Виж

français (FR) (128 KB - PDF)

Виж

hrvatski (HR) (150.39 KB - PDF)

Виж

italiano (IT) (126.79 KB - PDF)

Виж

latviešu (LV) (168.28 KB - PDF)

Виж

lietuvių (LT) (152 KB - PDF)

Виж

magyar (HU) (149.14 KB - PDF)

Виж

Malti (MT) (152.23 KB - PDF)

Виж

Nederlands (NL) (127.66 KB - PDF)

Виж

polski (PL) (153.03 KB - PDF)

Виж

português (PT) (129.04 KB - PDF)

Виж

română (RO) (148.26 KB - PDF)

Виж

slovenčina (SK) (152.34 KB - PDF)

Виж

slovenščina (SL) (149.23 KB - PDF)

Виж

suomi (FI) (125.71 KB - PDF)

Виж

svenska (SV) (126.4 KB - PDF)

Виж

Product information

български (BG) (1.02 MB - PDF)

Виж

español (ES) (759.51 KB - PDF)

Виж

čeština (CS) (1001.99 KB - PDF)

Виж

dansk (DA) (886.16 KB - PDF)

Виж

Deutsch (DE) (912.04 KB - PDF)

Виж

eesti (ET) (973.17 KB - PDF)

Виж

ελληνικά (EL) (1.07 MB - PDF)

Виж

français (FR) (1016.58 KB - PDF)

Виж

hrvatski (HR) (959.44 KB - PDF)

Виж

italiano (IT) (898.18 KB - PDF)

Виж

latviešu (LV) (968.27 KB - PDF)

Виж

lietuvių (LT) (949.26 KB - PDF)

Виж

magyar (HU) (1018.05 KB - PDF)

Виж

Malti (MT) (1017.44 KB - PDF)

Виж

Nederlands (NL) (876.74 KB - PDF)

Виж

polski (PL) (1016.8 KB - PDF)

Виж

português (PT) (890.47 KB - PDF)

Виж

română (RO) (1.03 MB - PDF)

Виж

slovenčina (SK) (1.02 MB - PDF)

Виж

slovenščina (SL) (950.21 KB - PDF)

Виж

suomi (FI) (887.75 KB - PDF)

Виж

svenska (SV) (889.06 KB - PDF)

Виж

Íslenska (IS) (870.77 KB - PDF)

Виж

norsk (NO) (868.11 KB - PDF)

Виж
Latest procedure affecting product information:PSUSA/00002113/202309
24/07/2024
icon globe

This medicine’s product information is available in all official EU languages.
Select 'available languages' to access the language you need.

 

Product information documents contain:

  • summary of product characteristics (annex I);
  • manufacturing authorisation holder responsible for batch release (annex IIA);
  • conditions of the marketing authorisation (annex IIB);
  • labelling (annex IIIA);
  • package leaflet (annex IIIB).

български (BG) (87.43 KB - PDF)

Виж

español (ES) (65 KB - PDF)

Виж

čeština (CS) (104.93 KB - PDF)

Виж

dansk (DA) (66.01 KB - PDF)

Виж

Deutsch (DE) (66.19 KB - PDF)

Виж

eesti (ET) (65.48 KB - PDF)

Виж

ελληνικά (EL) (87.8 KB - PDF)

Виж

français (FR) (68.57 KB - PDF)

Виж

hrvatski (HR) (82.73 KB - PDF)

Виж

italiano (IT) (63.93 KB - PDF)

Виж

latviešu (LV) (85.72 KB - PDF)

Виж

lietuvių (LT) (85.09 KB - PDF)

Виж

magyar (HU) (74.75 KB - PDF)

Виж

Malti (MT) (88.02 KB - PDF)

Виж

Nederlands (NL) (64.63 KB - PDF)

Виж

polski (PL) (89.14 KB - PDF)

Виж

português (PT) (65.5 KB - PDF)

Виж

română (RO) (75.31 KB - PDF)

Виж

slovenčina (SK) (103.63 KB - PDF)

Виж

slovenščina (SL) (103.72 KB - PDF)

Виж

suomi (FI) (64.66 KB - PDF)

Виж

svenska (SV) (86.31 KB - PDF)

Виж

Íslenska (IS) (65.52 KB - PDF)

Виж

norsk (NO) (65.84 KB - PDF)

Виж

Product details

Name of medicine
Suboxone
Active substance
  • buprenorphine
  • naloxone
International non-proprietary name (INN) or common name
  • buprenorphine
  • naloxone
Therapeutic area (MeSH)
Opioid-Related Disorders
Anatomical therapeutic chemical (ATC) code
N07BC51

Pharmacotherapeutic group

Other nervous system drugs

Therapeutic indication

Substitution treatment for opioid-drug dependence, within a framework of medical, social and psychological treatment. The intention of the naloxone component is to deter intravenous misuse. Treatment is intended for use in adults and adolescents over 15 years of age who have agreed to be treated for addiction.

Authorisation details

EMA product number
EMEA/H/C/000697
Marketing authorisation holder
Indivior Europe Limited

27 Windsor Place
Dublin 2
Ireland

Opinion adopted
27/07/2006
Marketing authorisation issued
26/09/2006
Withdrawal of marketing authorisation
11/09/2026
Revision
24

Assessment history

This page was last updated on

Share this page